MINDFuL
Phase 2 trial of XPro for early and mild Alzheimer’s disease
The MINDFuL study investigates XProTM in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation.
The MINDFuL study will compare XProTM to placebo (an injection that looks like the investigational drug but does not contain active medicine) to find out whether XProTM affects memory, functioning, and behavior. The study will also evaluate whether XProTM is safe and tolerable.
This study runs for 6 months in which some participants receive the study drug and some receive the placebo. During this time, measurements will be made by brain imaging (MRI), by blood collection, and cognitive testing. After this, a 12-month open label extension is offered in which all participants receive the study drug.
LAUREL
Phase I/open-label trial, dose escalation study of INKmune therapy
LAUREL is a Phase I/open-label trial, dose escalation study of INKmune therapy in patients with: - MDS-EB-1/2, MDS-CMML 1-2 who have completed treatment with Azacytidine (AZA), and not achieved complete remission (CR) who are not thought to be fit for intensive chemotherapy.
Patients with AML in complete remission (or complete remission with incomplete count recovery) unsuitable for intensive chemotherapy or allogeneic stem cell transplantation.
Patients with relapsed MDS or AML post-allogeneic stem cell transplant, with slowly progressive disease unsuitable for intensive chemotherapy.
The study is being conducted in the UK and Greece.
CaRe Prostate
Study of INKmune in Patients with metastatic castrate-resistant prostate cancer
CaRe Prostate is a Phase I/II, open label, dose escalation and expansion study of INKmune therapy in patients with metastatic castration resistant prostate cancer (mCRPC). The study is being conducted in the US.
footer contact
Interested to learn more? Please contact us at [email protected]
Contact Us
footer signup
Subscribe to receive the latest updates
Sign Up